Advicenne

Advicenne Dividend

Dividend of Advicenne (ALDVI.PA) as of Nov 22, 2026.

Dividend

0.00EUR

Last updated:

How much dividend does Advicenne 2026 pay?

According to the latest status from November 2026, Advicenne paid a total of 0.00 EUR per share in dividends within the last 12 months. With the current Advicenne price of 0.63 EUR, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Advicenne Dividends

Historical Advicenne Dividends
PaydateDividend

The Advicenne Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2020
0.00 EUR
Jan 1, 2021
0.00 EUR
Jan 1, 2022
0.00 EUR
Jan 1, 2023
0.00 EUR
Jan 1, 2024
0.00 EUR
Jan 1, 2025
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
The Advicenne Dividend history
YEARDividendYoY
est0.00EUR—
est0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—
0.00EUR—

Is the Advicenne Dividend Safe?

Advicenne has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Advicenne's Dividend Distributions

Advicenne’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Advicenne's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Advicenne's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Advicenne’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Advicenne Stock analysis

What does Advicenne do? Advicenne SA is a French pharmaceutical company specializing in the development of medications for rare and chronic diseases. The company was founded in 2007 by Dr. Luc-André Granier and is headquartered in Nîmes, France. Business model Advicenne develops its products based on proven technologies in the pharmaceutical industry. The company specializes in the development of medications for rare and chronic diseases, particularly for patients with kidney and metabolic disorders. The company implements a customer-oriented development strategy and is committed to close collaboration with doctors and patients. Advicenne has entered into various partnerships and licensing agreements with other pharmaceutical companies to distribute and further develop its products and technologies worldwide. Divisions Advicenne operates in various business areas, including the development of medications for kidney and metabolic disorders, as well as the marketing of products for patients with chronic diseases. Product portfolio The company currently offers three products: 1. Sibnayal: Sibnayal is a medication for the treatment of kidney diseases. It has been developed to prevent the disease-related loss of potassium in patients with kidney failure. The medication is currently approved for use in a clinical trial. 2. ADV7103: ADV7103 is a medication for the treatment of metabolic disorders. It has been developed to help patients with metabolic disorders such as phenylketonuria (PKU) and hypervalinemia (HV). The medication is currently approved under the name Orladeyo™ and is marketed in collaboration with Daiichi Sankyo Company, Limited. 3. ADV6209: ADV6209 is a medication for the treatment of chronic pain. It is targeted at patients who have not found sufficient pain relief due to chronic pain. The medication is currently in phase II of clinical trials. Advicenne has made significant investments in the development of innovative medications in recent years and has expanded its product pipeline to improve the therapeutic options for patients with rare and chronic diseases. Conclusion Advicenne is an emerging company in the pharmaceutical industry that focuses on the development of medications for rare and chronic diseases. The company aims to improve the lives of patients with its therapies and is committed to close collaboration with doctors and patients. Advicenne has already brought several promising products to market and continues to heavily invest in research and development to improve the therapeutic options for patients with rare and chronic diseases. Advicenne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advicenne stock

Advicenne paid dividends every year for the past 0 years.

Advicenne is assigned to the 'Health' sector.

The dividends of Advicenne are distributed in EUR.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Advicenne